
Episode Description
In this episode of Lab Rats to Unicorns, John Flavin sits down with Ryan Beal, M.D., founder and CEO of Dyve Biosciences. Ryan traces his path from medicine and consulting to biotech entrepreneurship, and how Dyve evolved from an early skincare concept into a transdermal drug delivery platform with applications in gout and oncology.
Ryan explains the science behind tumor acidity, why the acidic environment surrounding tumors can suppress immune activity and reduce the effectiveness of cancer therapies, and how Dyve’s lead oncology program, DYV800, is designed to overcome a longstanding drug delivery challenge. He also discusses the company’s work with Moffitt Cancer Center as it prepares to move the approach into cancer patients.
The conversation takes a deeply personal turn as Ryan shares his own cancer diagnosis and experience undergoing chemotherapy, surgery, and radiation while leading Dyve. He and John discuss how becoming a patient changed his perspective on urgency, the importance of a strong team, learning from skepticism, and why curiosity, perseverance, and gratitude continue to guide his work.
Weitere Episoden von „Lab Rats to Unicorns“



Verpasse keine Episode von “Lab Rats to Unicorns” und abonniere ihn in der kostenlosen GetPodcast App.








